A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of HER2, FHIT, AND APC expression status

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 693-701

  Bria, E ^a,b   De Manzoni, G ^c   Beghelli, S ^a   Tomezzoli, A ^c   Barbi, S ^c   Di Gregorio, C ^d   Scardoni, M ^a,c   Amato, E ^a   Frizziero, M ^b   Sperduti, I ^e   Corbo, V ^a   Brunelli, M ^c   Bersani, S ^a,c   Tortora, G ^b   Scarpa, A ^a,c  

^a Center for Applied Research in Cancer   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apc; Fhit; Gastric cancer; Her2; Prognosis; Score

Indexed keywords

APC PROTEIN; BETA CATENIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENDER; GENE DOSAGE; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK; RISK ASSESSMENT; RISK CLASSIFICATION; SCORING SYSTEM; STOMACH CANCER;

EID: 84874560562     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds506     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Kim B, Byun SJ, Kim YA et al.. Cell cycle regulators, APC/beta-catenin, NFkappaB and Epstein-Barr virus in gastric carcinomas. Pathology 2011; 42: 58-65.
3. Nagata T, Ichikawa D, Komatsu S et al.. Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol 2011; 104: 592-597.
4. Park SR, Kim MJ, Ryu KW et al.. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg 2011; 251: 428-435.
5. Begnami MD, Fukuda E, Fregnani JH et al.. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036.
6. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
7. Bragantini E, Barbi S, Beghelli S et al.. Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. J Cancer Res Clin Oncol 2006; 132: 45-50.
8. Capuzzi D, Santoro E, Hauck WW et al.. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000; 88: 24-34.
9. Rocco A, Schandl L, Chen J et al.. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 2003; 129: 84-88.
10. Beghelli S, de Manzoni G, Barbi S et al.. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006; 139: 347-356.
11. Scartozzi M, Galizia E, Freddari F et al.. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30: 451-459.
12. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 1999; 81: 1392-1397.
13. Zhou YN, Xu CP, Han B et al.. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol 2002; 8: 987-993.
14. Mattioli E, Vogiatzi P, Sun A et al.. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 2007; 210: 183-191.
15. Pinto-de-Sousa J, Silva F, David L et al.. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 2004; 44: 323-331.
16. Barbi S, Cataldo I, De Manzoni G et al.. The analysis of PIK3CA mutations in gastric carcinoma and meta-analysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010; 29: 32.
17. Li GC, Zhang Z, Ma XJ et al.. Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Mol Biol Rep 2011; 39: 399-405.
18. Li VS, Wong CW, Chan TL et al.. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29.
19. Iasonos A, Schrag D, Raj GV et al.. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008; 26: 1364-1370.
20. Alonzo TA. Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005; 23: 9053-9054.
21. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
22. Hofmann M, Stoss O, Shi D et al.. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
23. Kononen J, Bubendorf L, Kallioniemi A et al.. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
24. Brunelli M, Manfrin E, Martignoni G et al.. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for Herceptin therapy. Am J Clin Pathol 2008; 129: 907-911.
25. Brunello E, Brunelli M, Manfrin E et al.. Classical lobular breast carcinoma consistently lacks topoisomerase-IIalpha gene amplification: implications for the tailored use of anthracycline-based chemotherapies. Histopathology 2012; 60: 482-488.
26. Lal P, Salazar PA, Hudis CA et al.. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a singleinstitution experience of 2,279 cases and comparison of dual-color and singlecolor scoring. Am J Clin Pathol 2004; 121: 631-636.
27. de Manzoni G, Tomezzoli A, Di Leo A et al.. Clinical significance of mutator phenotype and chromosome 17p and 18q allelic loss in gastric cancer. Br J Surg 2001; 88: 419-425.
28. Moore PS, Zamboni G, Brighenti A et al.. Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. Am J Pathol 2001; 158: 317-321.
29. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991; 9: 191-192.
30. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 4: 187-200.
31. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14: 1707-1723.
32. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469-1482.
33. Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med 2009; 28: 389-411.
34. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23: 2109-2123.
35. Anne-Laure B, Carolin S. Maximally selected Chi-squared statistics and nonmonotonic associations: an exact approach based on two cutpoints. Comput Stat Data Anal 2007; 51: 6295-6306.
36. Bria E, Milella M, Sperduti I et al.. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in nonsmallcell lung cancer. Lung Cancer 2009; 66: 365-371.
37. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
38. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
39. Efficace F, Bottomley A, Smit EF et al.. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006; 17: 1698-1704.
40. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992; 11: 2093-2109.
41. Filsoufi F, Rahmanian PB, Castillo JG et al.. Logistic risk model predicting postoperative respiratory failure in patients undergoing valve surgery. Eur J Cardiothorac Surg 2008; 34: 953-959.
42. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. JAMA 1994; 272: 1049-1055.
43. Di Maio M, Lama N, Morabito A et al.. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010; 46: 735-743.
44. Harrell FEJ. Regression Modelling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer, 2001.
45. Paoletti X, Oba K, Burzykowski T et al.. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
46. Cho JY, Lim JY, Cheong JH et al.. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011; 17: 1850-1857.
47. Mohri Y, Tanaka K, Ohi M et al.. Prognostic significance of hostand tumor-related factors in patients with gastric cancer. World J Surg 2011; 34: 285-290.
48. Peeters KC, Kattan MW, Hartgrink HH et al.. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103: 702-707.
49. Bang YJ, Van Cutsem E, Feyereislova A et al.. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
50. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer 2012; 130: 2845-2856.
51. Kanta SY, Yamane T, Dobashi Y et al.. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 2006; 37: 1333-1343.
52. Liang Z, Zeng X, Gao J et al.. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8: 363.
53. Huiping C, Kristjansdottir S, Bergthorsson JT et al.. High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 2002; 38: 728-735.
54. Davies ML, Roberts GT, Stuart N et al.. Analysis of a panel of antibodies to APC reveals consistent activity towards an unidentified protein. Br J Cancer 2007; 97: 384-390.
55. An JY, Kim H, Cheong JH et al.. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131: 505-511.